Search

Displaying results 1921 - 1930 of 10000 in total
  1. Drug

    Fexinidazole

    go.drugbank.com/drugs/DB12265
    Approved

    Transmitted by the bite of an infected tsetse fly, HAT is biphasic with a first (hemolymphatic) stage that progresses to a second (meningoencephalitic) stage in which patients experience progressively … [A237555, A237560] Fexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021.

  2. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas … [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]

  3. Drug

    Mycophenolic acid

    go.drugbank.com/drugs/DB01024
    ApprovedInvestigational

    Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. … Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis.

    Synonyms: (e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acidCategories: UGT1A1 Substrates with a Narrow Therapeutic Index, UGT1A6 Substrates with a Narrow Therapeutic Index
  4. Drug

    Normethadone

    go.drugbank.com/drugs/DB11609
    ApprovedIllicit

    Normethadone is used as an opioid antitussive in combination with [DB11610]. It is marketed in Canada by Valeant under the tradename Cophylac.

  5. Drug

    Turoctocog alfa pegol

    go.drugbank.com/drugs/DB14738
    ApprovedInvestigational

    The essential difference between turoctocog alfa and N8-GP, however, is the specific attachment of a 40-kDa polyethylene glycol (PEG) group to a specific _O_-glycan in the truncated B-domain of the general … Turoctocog alfa pegol is a pegylated version of [turoctocog alfa]. Novo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019.

  6. Drug

    Fursultiamine

    go.drugbank.com/drugs/DB08966
    Approved

    Fursultiamine is a vitamin B1 derivative.

    Mixtures: ALINAMIN EX PLUS
  7. Drug

    Atomoxetine

    go.drugbank.com/drugs/DB00289
    ApprovedInvestigational

    [A18262] This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and striatum is associated with many stimulant-associated side effects and an increase in abuse potential, which … [A178090] Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum.

    Products: ATOMOXE 1A PHARMA 10MG, ATOMOXE 1A PHARMA 18MG
  8. Drug

    Trastuzumab

    go.drugbank.com/drugs/DB00072
    ApprovedInvestigational

    Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody [A40276] that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular … Herzuma (trastuzumab-pkrb) is a biosimilar drug approved in December 2018 for the treatment of HER2-overexpressing breast cancer.

  9. Drug

    Pipradrol

    go.drugbank.com/drugs/DB11584
    ApprovedWithdrawn

    Pipradrol was made illegal in many countries in 1970s because of its potential for abuse. It is currently classified under the Misuse of Drugs Act as a Class C substance [L2522]. … In addition to this, it has shown favorable effects in postpartum depressive symptoms [L2516].

  10. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    [A262076] Patients with cTTP have a severe deficiency of a plasma metalloproteinase called ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), which is responsible … [A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP.